Company Overview and News

Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-11 seekingalpha
Today we will discuss vTv Therapeutics (NASDAQ:VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s remains a difficult to treat area.
Upvote Downvote

Caladrius Biosciences to Participate at Upcoming April Conferences

2018-04-09 globenewswire
BASKING RIDGE, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Douglas Losordo, M.D., FACC, FAHA, Senior Vice President of Clinical Medical and Regulatory Affairs and Chief Medical Officer, will participate at the following conferences in April:
Upvote Downvote

Caladrius Biosciences to Present at The MicroCap Conference

2018-04-03 globenewswire
BASKING RIDGE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Joe Talamo, Senior Vice President and Chief Financial Officer, will present a corporate overview at The MicroCap Conference on Monday, April 9th at 1:30 p.
Upvote Downvote

CLBS / Caladrius Biosciences, Inc. 10-K/A (Annual Report)

Upvote Downvote

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript

2018-03-22 seekingalpha
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q4 2017 Results Earnings Conference Call March 22, 2018 4:30 PM ET
Upvote Downvote

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

2018-03-22 reuters
Upvote Downvote

CLBS / Caladrius Biosciences, Inc. 10-K (Annual Report)

Upvote Downvote

Your Daily Pharma Scoop: Progenics Rallies, Merck To Partner With Eisai, Teva Upsizes Debt Offering

2018-03-09 seekingalpha
Today we will discuss Progenics Pharmaceuticals (PGNX), which is rallying after robust Relistor sales figures for the fourth quarter. Relistor has been out-licensed to Valeant (VRX) and Progenics gets a 15% royalty on net sales.
Upvote Downvote

Caladrius Snatches Itself A Clinical Candidate For Heart Disease

2018-03-07 seekingalpha
The purchase of the CD34+ program was based on positive data stemming from multiple clinical trials proving that the drug works in the intended population.
Upvote Downvote

BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

2018-03-06 reuters
Upvote Downvote

CLBS / Caladrius Biosciences, Inc. 8-K (Current Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 8, 2018 CALADRIUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-33650 (Commission File Number) 22-2343568 (IRS Employer Identification No.
Upvote Downvote

CLBS / Caladrius Biosciences, Inc. 424B5 (Prospectus)

Document Filed Pursuant to Rule 424(b)(5) Registration No. 333-206175 PROSPECTUS SUPPLEMENT (To Prospectus dated August 28, 2015) $12,000,000 Common Stock We have entered into a common stock sales agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying prospectus.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

CUSIP: 128058104